 Whitney High
Concepts (386)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 16 | 2024 | 849 | 2.390 |
Why?
| | Melanoma | 13 | 2020 | 757 | 2.170 |
Why?
| | Skin Diseases | 10 | 2013 | 149 | 1.970 |
Why?
| | Dermatology | 5 | 2013 | 124 | 1.270 |
Why?
| | Skin Diseases, Vesiculobullous | 4 | 2011 | 18 | 1.230 |
Why?
| | Immunohistochemistry | 14 | 2020 | 1739 | 1.070 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 6 | 2012 | 8 | 1.000 |
Why?
| | Nevus, Pigmented | 4 | 2020 | 32 | 0.940 |
Why?
| | Gadolinium DTPA | 6 | 2012 | 70 | 0.880 |
Why?
| | Bedbugs | 2 | 2017 | 2 | 0.870 |
Why?
| | Contrast Media | 9 | 2012 | 462 | 0.790 |
Why?
| | Malpractice | 3 | 2013 | 38 | 0.770 |
Why?
| | Skin | 11 | 2011 | 750 | 0.750 |
Why?
| | Lupus Erythematosus, Cutaneous | 3 | 2007 | 8 | 0.730 |
Why?
| | Gadolinium | 4 | 2010 | 82 | 0.730 |
Why?
| | Dermatitis, Allergic Contact | 3 | 2006 | 72 | 0.640 |
Why?
| | Psoriasis | 3 | 2013 | 102 | 0.590 |
Why?
| | Kidney Failure, Chronic | 3 | 2009 | 560 | 0.590 |
Why?
| | Skin Ulcer | 1 | 2018 | 14 | 0.580 |
Why?
| | Seminoma | 1 | 2018 | 20 | 0.570 |
Why?
| | Histiocytosis, Langerhans-Cell | 2 | 2008 | 38 | 0.570 |
Why?
| | Ectoparasitic Infestations | 1 | 2017 | 5 | 0.540 |
Why?
| | Dermatitis, Atopic | 3 | 2013 | 325 | 0.520 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 77 | 0.520 |
Why?
| | Testicular Neoplasms | 1 | 2018 | 110 | 0.510 |
Why?
| | Erythema | 3 | 2009 | 29 | 0.500 |
Why?
| | Scrotum | 2 | 2018 | 27 | 0.500 |
Why?
| | Nail Diseases | 2 | 2006 | 8 | 0.490 |
Why?
| | Fibrosis | 6 | 2008 | 552 | 0.450 |
Why?
| | Medicare | 1 | 2020 | 745 | 0.450 |
Why?
| | Humans | 70 | 2024 | 136899 | 0.440 |
Why?
| | Neurothekeoma | 1 | 2014 | 4 | 0.440 |
Why?
| | Defensive Medicine | 1 | 2013 | 4 | 0.440 |
Why?
| | Telepathology | 1 | 2013 | 4 | 0.430 |
Why?
| | Licensure | 1 | 2013 | 13 | 0.430 |
Why?
| | Diagnostic Errors | 2 | 2012 | 170 | 0.430 |
Why?
| | Antibodies, Monoclonal | 3 | 2014 | 1417 | 0.410 |
Why?
| | Lupus Erythematosus, Discoid | 2 | 2015 | 8 | 0.370 |
Why?
| | Scabies | 1 | 2011 | 2 | 0.370 |
Why?
| | Elephantiasis | 1 | 2011 | 3 | 0.360 |
Why?
| | Hidradenitis Suppurativa | 1 | 2011 | 10 | 0.360 |
Why?
| | Ganglion Cysts | 1 | 2011 | 10 | 0.360 |
Why?
| | Acromioclavicular Joint | 1 | 2011 | 11 | 0.360 |
Why?
| | Genital Diseases, Male | 1 | 2011 | 17 | 0.360 |
Why?
| | Diagnosis, Differential | 10 | 2024 | 1484 | 0.350 |
Why?
| | Male | 39 | 2024 | 67308 | 0.340 |
Why?
| | Biopsy | 7 | 2021 | 1130 | 0.340 |
Why?
| | Piperazines | 2 | 2012 | 349 | 0.330 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1271 | 0.330 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 12 | 0.320 |
Why?
| | Cocaine | 2 | 2012 | 165 | 0.310 |
Why?
| | Spectrometry, Fluorescence | 1 | 2009 | 171 | 0.310 |
Why?
| | Keratoacanthoma | 1 | 2008 | 2 | 0.310 |
Why?
| | Keratolytic Agents | 1 | 2008 | 5 | 0.310 |
Why?
| | Pyrimidines | 2 | 2012 | 472 | 0.300 |
Why?
| | Isotretinoin | 1 | 2008 | 26 | 0.300 |
Why?
| | Antineoplastic Agents | 3 | 2010 | 2140 | 0.300 |
Why?
| | Hypersensitivity, Delayed | 1 | 2008 | 28 | 0.300 |
Why?
| | Syphilis | 2 | 2005 | 33 | 0.290 |
Why?
| | Pyroglyphidae | 1 | 2008 | 19 | 0.290 |
Why?
| | Pathology, Clinical | 1 | 2008 | 37 | 0.290 |
Why?
| | Adult | 28 | 2020 | 37595 | 0.290 |
Why?
| | Sweet Syndrome | 1 | 2007 | 8 | 0.290 |
Why?
| | Female | 37 | 2020 | 72703 | 0.280 |
Why?
| | Kidney Diseases | 2 | 2008 | 405 | 0.280 |
Why?
| | Scleroderma, Systemic | 1 | 2008 | 122 | 0.280 |
Why?
| | Middle Aged | 25 | 2024 | 33118 | 0.270 |
Why?
| | Alopecia | 2 | 2013 | 32 | 0.270 |
Why?
| | Skin Diseases, Infectious | 1 | 2007 | 16 | 0.270 |
Why?
| | Dermatomyositis | 2 | 2004 | 27 | 0.270 |
Why?
| | Body Piercing | 1 | 2006 | 3 | 0.270 |
Why?
| | Antibodies, Antinuclear | 2 | 2004 | 70 | 0.260 |
Why?
| | Histiocytoma | 1 | 2006 | 2 | 0.260 |
Why?
| | Hemangiopericytoma | 1 | 2006 | 5 | 0.260 |
Why?
| | Epithelioid Cells | 1 | 2006 | 9 | 0.260 |
Why?
| | Communicable Diseases, Emerging | 1 | 2007 | 35 | 0.260 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2007 | 43 | 0.260 |
Why?
| | Granuloma, Pyogenic | 1 | 2006 | 9 | 0.260 |
Why?
| | Dermatitis, Seborrheic | 1 | 2006 | 4 | 0.260 |
Why?
| | Aged | 21 | 2021 | 23641 | 0.260 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 44 | 0.260 |
Why?
| | Exanthema | 1 | 2007 | 77 | 0.260 |
Why?
| | Granuloma | 1 | 2006 | 91 | 0.250 |
Why?
| | Titanium | 1 | 2006 | 82 | 0.250 |
Why?
| | Hyperkeratosis, Epidermolytic | 1 | 2005 | 21 | 0.250 |
Why?
| | Neoplasm Regression, Spontaneous | 1 | 2005 | 3 | 0.240 |
Why?
| | Genital Diseases, Female | 1 | 2005 | 27 | 0.240 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 99 | 0.240 |
Why?
| | Scalp | 1 | 2005 | 36 | 0.240 |
Why?
| | Ossification, Heterotopic | 1 | 2004 | 16 | 0.230 |
Why?
| | Ear, External | 1 | 2004 | 24 | 0.230 |
Why?
| | Tacrolimus | 1 | 2006 | 199 | 0.230 |
Why?
| | Ear Diseases | 1 | 2004 | 15 | 0.230 |
Why?
| | Allergens | 1 | 2008 | 405 | 0.230 |
Why?
| | Quinazolines | 1 | 2006 | 249 | 0.230 |
Why?
| | Telemedicine | 1 | 2013 | 843 | 0.230 |
Why?
| | Tuberculosis, Miliary | 1 | 2004 | 5 | 0.220 |
Why?
| | Tuberculosis, Cutaneous | 1 | 2004 | 3 | 0.220 |
Why?
| | Antigens, CD20 | 1 | 2024 | 28 | 0.220 |
Why?
| | CD56 Antigen | 1 | 2024 | 36 | 0.220 |
Why?
| | Mycosis Fungoides | 1 | 2024 | 61 | 0.220 |
Why?
| | Agave | 1 | 2003 | 1 | 0.220 |
Why?
| | Biopsy, Needle | 5 | 2011 | 191 | 0.220 |
Why?
| | Fibroma | 1 | 2004 | 22 | 0.220 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2010 | 683 | 0.210 |
Why?
| | Tumor Virus Infections | 1 | 2003 | 47 | 0.210 |
Why?
| | Alendronate | 1 | 2003 | 15 | 0.210 |
Why?
| | Protein Kinase Inhibitors | 2 | 2012 | 919 | 0.210 |
Why?
| | Facial Dermatoses | 1 | 2003 | 16 | 0.210 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2004 | 125 | 0.210 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 346 | 0.200 |
Why?
| | Vasculitis | 1 | 2003 | 65 | 0.200 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 510 | 0.200 |
Why?
| | Hyperpigmentation | 1 | 2003 | 26 | 0.200 |
Why?
| | Papillomaviridae | 1 | 2003 | 125 | 0.200 |
Why?
| | Women's Health | 1 | 2005 | 371 | 0.200 |
Why?
| | Cicatrix | 1 | 2003 | 64 | 0.200 |
Why?
| | Pregnancy Outcome | 1 | 2005 | 410 | 0.200 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 349 | 0.190 |
Why?
| | Antirheumatic Agents | 1 | 2005 | 290 | 0.190 |
Why?
| | United States | 7 | 2020 | 14595 | 0.190 |
Why?
| | Cheilitis | 1 | 2021 | 3 | 0.190 |
Why?
| | Prognosis | 5 | 2017 | 4011 | 0.180 |
Why?
| | Patch Tests | 3 | 2008 | 56 | 0.180 |
Why?
| | MART-1 Antigen | 1 | 2020 | 12 | 0.170 |
Why?
| | SOXE Transcription Factors | 1 | 2020 | 19 | 0.160 |
Why?
| | Pregnancy Complications | 1 | 2005 | 521 | 0.160 |
Why?
| | Genetic Testing | 2 | 2017 | 453 | 0.160 |
Why?
| | Cannabis | 1 | 2007 | 478 | 0.160 |
Why?
| | Benzamides | 2 | 2012 | 218 | 0.160 |
Why?
| | Pulmonary Fibrosis | 1 | 2003 | 397 | 0.160 |
Why?
| | Aged, 80 and over | 8 | 2015 | 7552 | 0.160 |
Why?
| | Societies, Medical | 1 | 2003 | 816 | 0.160 |
Why?
| | Papillomavirus Infections | 1 | 2003 | 330 | 0.160 |
Why?
| | HIV Infections | 2 | 2004 | 2822 | 0.150 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 617 | 0.150 |
Why?
| | Retrospective Studies | 9 | 2020 | 15514 | 0.150 |
Why?
| | Methotrexate | 3 | 2012 | 255 | 0.140 |
Why?
| | Dermoscopy | 2 | 2017 | 10 | 0.140 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 307 | 0.140 |
Why?
| | Comparative Genomic Hybridization | 1 | 2017 | 30 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2019 | 316 | 0.140 |
Why?
| | Lip | 2 | 2021 | 23 | 0.140 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 202 | 0.140 |
Why?
| | Pruritus | 2 | 2009 | 61 | 0.140 |
Why?
| | Bites and Stings | 1 | 2017 | 32 | 0.130 |
Why?
| | Risk Assessment | 6 | 2011 | 3432 | 0.130 |
Why?
| | Severity of Illness Index | 4 | 2009 | 2833 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 1 | 2019 | 328 | 0.130 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2017 | 319 | 0.130 |
Why?
| | Lichenoid Eruptions | 1 | 2015 | 3 | 0.130 |
Why?
| | Dermatologic Agents | 2 | 2013 | 69 | 0.130 |
Why?
| | Sampling Studies | 2 | 2007 | 100 | 0.120 |
Why?
| | Mutation | 1 | 2007 | 3948 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2011 | 5126 | 0.120 |
Why?
| | Renal Dialysis | 2 | 2009 | 434 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 4 | 2011 | 3710 | 0.110 |
Why?
| | Child, Preschool | 4 | 2014 | 11013 | 0.110 |
Why?
| | Child | 6 | 2014 | 21896 | 0.110 |
Why?
| | Face | 1 | 2015 | 175 | 0.110 |
Why?
| | Insurance, Liability | 1 | 2013 | 5 | 0.110 |
Why?
| | Mass Spectrometry | 2 | 2008 | 741 | 0.110 |
Why?
| | Mohs Surgery | 2 | 2004 | 27 | 0.110 |
Why?
| | Liability, Legal | 1 | 2013 | 43 | 0.110 |
Why?
| | Animals | 8 | 2019 | 36915 | 0.110 |
Why?
| | Internship and Residency | 1 | 2003 | 1131 | 0.100 |
Why?
| | Photography | 1 | 2013 | 95 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1769 | 0.100 |
Why?
| | Antinematodal Agents | 1 | 2012 | 6 | 0.100 |
Why?
| | Imatinib Mesylate | 2 | 2012 | 79 | 0.100 |
Why?
| | Levamisole | 1 | 2012 | 19 | 0.100 |
Why?
| | Drug Contamination | 1 | 2012 | 51 | 0.100 |
Why?
| | Fetal Diseases | 1 | 2013 | 171 | 0.090 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2012 | 44 | 0.090 |
Why?
| | Carcinoma, Basal Cell | 2 | 2010 | 75 | 0.090 |
Why?
| | Argyria | 1 | 2011 | 4 | 0.090 |
Why?
| | Immunosuppressive Agents | 2 | 2009 | 886 | 0.090 |
Why?
| | Granuloma, Foreign-Body | 1 | 2011 | 10 | 0.090 |
Why?
| | Orphanages | 1 | 2011 | 3 | 0.090 |
Why?
| | Vietnam | 1 | 2011 | 28 | 0.090 |
Why?
| | Ethiopia | 1 | 2011 | 41 | 0.090 |
Why?
| | Durapatite | 1 | 2011 | 37 | 0.090 |
Why?
| | Foreign-Body Migration | 1 | 2011 | 34 | 0.090 |
Why?
| | Synovial Fluid | 1 | 2011 | 69 | 0.090 |
Why?
| | Adoption | 1 | 2011 | 32 | 0.090 |
Why?
| | Cocaine-Related Disorders | 1 | 2012 | 113 | 0.090 |
Why?
| | Rupture | 1 | 2011 | 93 | 0.090 |
Why?
| | Pilot Projects | 2 | 2006 | 1684 | 0.090 |
Why?
| | Mucins | 1 | 2011 | 74 | 0.090 |
Why?
| | Rotator Cuff Injuries | 1 | 2011 | 60 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2020 | 1945 | 0.090 |
Why?
| | Transcription Factors | 1 | 2019 | 1715 | 0.090 |
Why?
| | China | 1 | 2011 | 218 | 0.090 |
Why?
| | Health Care Costs | 1 | 2013 | 386 | 0.080 |
Why?
| | Aminolevulinic Acid | 1 | 2010 | 4 | 0.080 |
Why?
| | Injections, Intralesional | 1 | 2010 | 34 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2012 | 10768 | 0.080 |
Why?
| | Eccrine Glands | 1 | 2009 | 2 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2018 | 1976 | 0.080 |
Why?
| | Synchrotrons | 1 | 2009 | 13 | 0.080 |
Why?
| | Practice Guidelines as Topic | 2 | 2008 | 1575 | 0.080 |
Why?
| | Iron-Dextran Complex | 1 | 2009 | 7 | 0.080 |
Why?
| | Guatemala | 1 | 2011 | 333 | 0.080 |
Why?
| | Photopheresis | 1 | 2009 | 9 | 0.080 |
Why?
| | Ultraviolet Therapy | 1 | 2009 | 16 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 88 | 0.080 |
Why?
| | Plasmapheresis | 1 | 2009 | 24 | 0.080 |
Why?
| | Observation | 1 | 2009 | 52 | 0.080 |
Why?
| | Adolescent | 5 | 2014 | 21402 | 0.080 |
Why?
| | Arthropod Vectors | 1 | 2009 | 7 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1695 | 0.080 |
Why?
| | Bedding and Linens | 1 | 2009 | 11 | 0.080 |
Why?
| | Naphthoquinones | 1 | 2009 | 19 | 0.080 |
Why?
| | Hyaluronic Acid | 1 | 2011 | 223 | 0.080 |
Why?
| | Rituximab | 1 | 2010 | 172 | 0.080 |
Why?
| | Fluorouracil | 1 | 2010 | 213 | 0.080 |
Why?
| | Vitiligo | 1 | 2009 | 42 | 0.080 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 107 | 0.080 |
Why?
| | Interferon-alpha | 1 | 2010 | 198 | 0.080 |
Why?
| | Erythropoietin | 1 | 2009 | 95 | 0.070 |
Why?
| | Bleomycin | 1 | 2010 | 247 | 0.070 |
Why?
| | Histiocytes | 1 | 2008 | 7 | 0.070 |
Why?
| | Histiocytosis | 1 | 2008 | 7 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2010 | 455 | 0.070 |
Why?
| | Langerhans Cells | 1 | 2008 | 12 | 0.070 |
Why?
| | Diabetes Insipidus | 1 | 2008 | 6 | 0.070 |
Why?
| | Carcinoma, Skin Appendage | 1 | 2007 | 2 | 0.070 |
Why?
| | Failure to Thrive | 1 | 2008 | 29 | 0.070 |
Why?
| | Prednisone | 2 | 2012 | 239 | 0.070 |
Why?
| | Antigen-Presenting Cells | 1 | 2008 | 156 | 0.070 |
Why?
| | Imidazoles | 1 | 2009 | 244 | 0.070 |
Why?
| | Microtubule-Associated Proteins | 1 | 2009 | 197 | 0.070 |
Why?
| | Medical Records | 1 | 2008 | 173 | 0.070 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2008 | 137 | 0.070 |
Why?
| | Bone Diseases | 1 | 2008 | 63 | 0.070 |
Why?
| | Risk Management | 1 | 2008 | 91 | 0.070 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 658 | 0.070 |
Why?
| | Gnathostoma | 1 | 2007 | 1 | 0.070 |
Why?
| | Pythium | 1 | 2007 | 1 | 0.070 |
Why?
| | Spirurida Infections | 1 | 2007 | 1 | 0.070 |
Why?
| | Amoeba | 1 | 2007 | 3 | 0.070 |
Why?
| | Keratinocytes | 1 | 2008 | 248 | 0.070 |
Why?
| | Amebiasis | 1 | 2007 | 5 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 7 | 0.070 |
Why?
| | Penicillium | 1 | 2007 | 7 | 0.070 |
Why?
| | Electron Probe Microanalysis | 1 | 2006 | 3 | 0.070 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2007 | 14 | 0.070 |
Why?
| | Genes, p16 | 1 | 2007 | 20 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2020 | 3528 | 0.070 |
Why?
| | Skull | 1 | 2008 | 138 | 0.070 |
Why?
| | Epidermis | 1 | 2007 | 157 | 0.070 |
Why?
| | Factor XIIIa | 1 | 2006 | 5 | 0.070 |
Why?
| | Paraffin Embedding | 1 | 2006 | 32 | 0.070 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 24 | 0.070 |
Why?
| | Dermis | 1 | 2006 | 33 | 0.060 |
Why?
| | Hypopigmentation | 1 | 2006 | 3 | 0.060 |
Why?
| | Dosage Forms | 1 | 2006 | 12 | 0.060 |
Why?
| | Pregnancy | 3 | 2013 | 6715 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1240 | 0.060 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2006 | 202 | 0.060 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 19 | 0.060 |
Why?
| | Lysosomes | 1 | 2006 | 142 | 0.060 |
Why?
| | Diabetic Nephropathies | 1 | 2009 | 291 | 0.060 |
Why?
| | Organ Specificity | 1 | 2006 | 304 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2006 | 288 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2006 | 330 | 0.060 |
Why?
| | Metals | 1 | 2006 | 136 | 0.060 |
Why?
| | Acidosis | 1 | 2006 | 101 | 0.060 |
Why?
| | Viscera | 1 | 2005 | 17 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 162 | 0.060 |
Why?
| | Pregnancy, Multiple | 1 | 2005 | 17 | 0.060 |
Why?
| | Radiography | 1 | 2008 | 834 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5077 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 40 | 0.060 |
Why?
| | Mitosis | 1 | 2006 | 193 | 0.060 |
Why?
| | Rare Diseases | 1 | 2005 | 100 | 0.060 |
Why?
| | Treponema pallidum | 1 | 2004 | 8 | 0.060 |
Why?
| | Foot | 1 | 2005 | 93 | 0.060 |
Why?
| | Pregnancy Trimester, Third | 1 | 2005 | 113 | 0.060 |
Why?
| | Urticaria | 1 | 2005 | 38 | 0.060 |
Why?
| | Infliximab | 1 | 2005 | 105 | 0.060 |
Why?
| | Knee Joint | 1 | 2008 | 400 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2006 | 157 | 0.060 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2007 | 225 | 0.060 |
Why?
| | Sclerosis | 1 | 2004 | 13 | 0.060 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 328 | 0.060 |
Why?
| | Glucocorticoids | 2 | 2012 | 596 | 0.060 |
Why?
| | Hand | 1 | 2005 | 160 | 0.060 |
Why?
| | Iron | 1 | 2006 | 313 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2005 | 411 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2007 | 6043 | 0.050 |
Why?
| | Infant | 2 | 2008 | 9408 | 0.050 |
Why?
| | Staining and Labeling | 1 | 2004 | 146 | 0.050 |
Why?
| | Kidney Transplantation | 1 | 2010 | 695 | 0.050 |
Why?
| | Nails | 1 | 2003 | 13 | 0.050 |
Why?
| | Twins | 1 | 2005 | 253 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1400 | 0.050 |
Why?
| | Chest Pain | 1 | 2004 | 91 | 0.050 |
Why?
| | Quality of Health Care | 1 | 2008 | 626 | 0.050 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2009 | 608 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2006 | 615 | 0.050 |
Why?
| | Arm | 1 | 2003 | 106 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2024 | 318 | 0.050 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 614 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 305 | 0.050 |
Why?
| | Atrophy | 1 | 2003 | 184 | 0.050 |
Why?
| | Plant Leaves | 1 | 2003 | 147 | 0.050 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2006 | 531 | 0.050 |
Why?
| | Hip Dislocation | 1 | 2002 | 55 | 0.050 |
Why?
| | Cohort Studies | 3 | 2008 | 5711 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 849 | 0.050 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2004 | 256 | 0.050 |
Why?
| | Blotting, Western | 1 | 2004 | 1227 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2005 | 552 | 0.050 |
Why?
| | Coronary Disease | 1 | 2004 | 385 | 0.040 |
Why?
| | Plasma Cells | 1 | 2021 | 71 | 0.040 |
Why?
| | Hip Joint | 1 | 2002 | 170 | 0.040 |
Why?
| | Young Adult | 2 | 2015 | 13157 | 0.040 |
Why?
| | Age Factors | 1 | 2008 | 3290 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1376 | 0.040 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2002 | 147 | 0.040 |
Why?
| | Osteoporosis | 1 | 2003 | 241 | 0.040 |
Why?
| | Reoperation | 1 | 2002 | 568 | 0.040 |
Why?
| | Respiratory Insufficiency | 1 | 2003 | 316 | 0.040 |
Why?
| | Rats, Wistar | 2 | 2012 | 457 | 0.040 |
Why?
| | Risk Factors | 3 | 2009 | 10313 | 0.040 |
Why?
| | Kidney | 1 | 2007 | 1460 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1689 | 0.040 |
Why?
| | Genotype | 1 | 2003 | 1906 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 974 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2416 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 1079 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2019 | 220 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 696 | 0.030 |
Why?
| | Clinical Competence | 1 | 2003 | 1086 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1159 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2020 | 419 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1996 | 0.030 |
Why?
| | Phenotype | 1 | 2024 | 3201 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 320 | 0.030 |
Why?
| | Minoxidil | 1 | 2013 | 1 | 0.030 |
Why?
| | Retinoids | 1 | 2013 | 33 | 0.030 |
Why?
| | Acne Vulgaris | 1 | 2013 | 28 | 0.030 |
Why?
| | Hydroxychloroquine | 1 | 2013 | 59 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2490 | 0.030 |
Why?
| | Inflammation | 1 | 2004 | 2817 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2003 | 5398 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2004 | 2033 | 0.020 |
Why?
| | Rats | 2 | 2012 | 5675 | 0.020 |
Why?
| | Injections, Intradermal | 1 | 2011 | 13 | 0.020 |
Why?
| | Cosmetic Techniques | 1 | 2011 | 20 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2744 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3396 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 973 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 5730 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2011 | 434 | 0.020 |
Why?
| | Incidence | 2 | 2010 | 2783 | 0.020 |
Why?
| | Epoetin Alfa | 1 | 2009 | 9 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2009 | 208 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1060 | 0.020 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2009 | 48 | 0.020 |
Why?
| | Drug Synergism | 1 | 2009 | 379 | 0.020 |
Why?
| | Keratin-15 | 1 | 2007 | 16 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 286 | 0.020 |
Why?
| | Axilla | 1 | 2006 | 47 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1357 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1262 | 0.020 |
Why?
| | Silver Staining | 1 | 2004 | 17 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2066 | 0.010 |
Why?
| | Databases, Factual | 1 | 2010 | 1345 | 0.010 |
Why?
| | Echocardiography, Stress | 1 | 2004 | 25 | 0.010 |
Why?
| | Causality | 1 | 2004 | 126 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1233 | 0.010 |
Why?
| | Probability | 1 | 2002 | 311 | 0.010 |
Why?
| | Age Distribution | 1 | 2002 | 391 | 0.010 |
Why?
| | Mice | 1 | 2019 | 17775 | 0.010 |
Why?
| | Sex Distribution | 1 | 2002 | 378 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 2004 | 208 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 533 | 0.010 |
Why?
| | Electroencephalography | 1 | 2004 | 436 | 0.010 |
Why?
| | Acute Disease | 1 | 2004 | 1000 | 0.010 |
Why?
| | Exercise Test | 1 | 2004 | 621 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 1058 | 0.010 |
Why?
| | Survival Analysis | 1 | 2004 | 1320 | 0.010 |
Why?
| | Joint Instability | 1 | 2002 | 170 | 0.010 |
Why?
| | Hospitalization | 1 | 2004 | 2183 | 0.010 |
Why?
|
|
High's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|